<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5630736</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.962</article-id><article-id pub-id-type="publisher-id">ofx163.962</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Bezlotoxumab (BEZ) for Prevention of <italic>Clostridium Difficile</italic> Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Golan</surname><given-names>Yoav</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>DuPont</surname><given-names>Herbert L</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Aldomiro</surname><given-names>Fernando</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Jensen</surname><given-names>Erin H</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Hanson</surname><given-names>Mary E</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Dorr</surname><given-names>Mary Beth</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Tufts Medical Center</institution>, <addr-line>Boston, Massachusetts</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>University of Texas School of Public Health</institution>, <addr-line>Houston, Texas</addr-line></aff><aff id="AF0003">
<label>3</label>
<institution>Baylor St. Luke’s Medical Center</institution>, <addr-line>Houston, Texas</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>Hospital Dr. Fernando Fonseca, EPE – Amadora/Sintra</institution>, <addr-line>Amadora/Sintra</addr-line>, <country>Portugal</country></aff><aff id="AF0005">
<label>5</label>
<institution>Merck &amp; Co., Inc.</institution>, <addr-line>Kenilworth, New Jersey</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 148. C. difficile: From the Bench to Bedside</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S387</fpage><lpage>S387</lpage><permissions><copyright-statement>© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.962.pdf"></self-uri><abstract><title><offsets xml_i="4682" xml_f="4690" txt_i="11" txt_f="19">Abstract</offsets></title><sec id="s1"><title><offsets xml_i="4718" xml_f="4728" txt_i="20" txt_f="30">Background</offsets></title><p><offsets xml_i="4739" xml_f="4883" txt_i="31" txt_f="175">CDI in patients with SRI is harder to treat and is associated with higher recurrence. MODIFY I/II found that BEZ, a monoclonal antibody against </offsets><italic><offsets xml_i="4891" xml_f="4903" txt_i="175" txt_f="187">C. difficile</offsets></italic><offsets xml_i="4912" xml_f="5119" txt_i="187" txt_f="394"> toxin B, is superior to placebo (PBO) at preventing rCDI in patients receiving standard of care antibiotics (SoC). This post hoc analysis assessed efficacy of BEZ in patients with SRI in the MODIFY studies.</offsets></p></sec><sec id="s2"><title><offsets xml_i="5149" xml_f="5156" txt_i="396" txt_f="403">Methods</offsets></title><p><offsets xml_i="5167" xml_f="5448" txt_i="404" txt_f="682">MODIFY I/II mITT populations were pooled to estimate initial clinical cure (ICC), rCDI, and mortality through 12 weeks. Estimated glomerular filtration rate (eGFR) was calculated with the Modified Diet in Renal Disease (MDRD) method. SRI was defined as eGFR &lt;60 mL/minute/1.73 m</offsets><sup><offsets xml_i="5453" xml_f="5454" txt_i="682" txt_f="683">2</offsets></sup><offsets xml_i="5460" xml_f="5582" txt_i="683" txt_f="805">. ICC was defined as SOC ≤16 days and no diarrhea on the 2 days after SoC end. rCDI was defined as diarrhea and toxigenic </offsets><italic><offsets xml_i="5590" xml_f="5602" txt_i="805" txt_f="817">C. difficile</offsets></italic><offsets xml_i="5611" xml_f="5682" txt_i="817" txt_f="888"> in stool. Mortality within 90 days after randomization was summarized.</offsets></p></sec><sec id="s3"><title><offsets xml_i="5712" xml_f="5719" txt_i="890" txt_f="897">Results</offsets></title><p><offsets xml_i="5730" xml_f="5783" txt_i="898" txt_f="951">Of the included 1554 patients, 1101 had no SRI (≥90: </offsets><italic><offsets xml_i="5791" xml_f="5794" txt_i="951" txt_f="954">n =</offsets></italic><offsets xml_i="5803" xml_f="5824" txt_i="954" txt_f="972"> 612; 60 to &lt; 90: </offsets><italic><offsets xml_i="5832" xml_f="5835" txt_i="972" txt_f="975">n =</offsets></italic><offsets xml_i="5844" xml_f="5878" txt_i="975" txt_f="1006"> 489); 430 had SRI (30 to &lt;60: </offsets><italic><offsets xml_i="5886" xml_f="5889" txt_i="1006" txt_f="1009">n =</offsets></italic><offsets xml_i="5898" xml_f="5918" txt_i="1009" txt_f="1026"> 290; 15 to &lt;30: </offsets><italic><offsets xml_i="5926" xml_f="5929" txt_i="1026" txt_f="1029">n =</offsets></italic><offsets xml_i="5938" xml_f="5951" txt_i="1029" txt_f="1039"> 71; &lt;15: </offsets><italic><offsets xml_i="5959" xml_f="5962" txt_i="1039" txt_f="1042">n =</offsets></italic><offsets xml_i="5971" xml_f="6742" txt_i="1042" txt_f="1813"> 69); 23 had unknown eGFR. 87% of SRI patients had ≥1 risk factor for rCDI. Relative to patients without SRI, more patients with SRI were ≥65 years (69% vs. 44%), immunocompromised (25 vs. 20%), had ribotype 027 (25% vs. 17%), and used concomitant antibiotics during SoC (41% vs. 31%) or after SoC (36% vs. 28%). SRI patients had more severe CDI (21% vs. 14%), lower CDI cure (78.4% vs. 80.1%), higher rCDI (31.6% vs. 27.8%), and death (11.6% vs. 5.3%) In the SRI cohort, more BEZ vs. PBO patients were inpatients (81% vs. 72%), ≥65 years (72% vs. 65%), immunocompromised (28 vs. 22%), and used systemic antibiotics after SoC ended (40% vs. 32%). The rate of ICC was similar between treatment groups and the rCDI rate was significantly less the BEZ vs. PBO group (Table).</offsets></p></sec><sec id="s4"><title><offsets xml_i="6772" xml_f="6782" txt_i="1815" txt_f="1825">Conclusion</offsets></title><p><offsets xml_i="6793" xml_f="6952" txt_i="1826" txt_f="1985">SRI was associated with worse CDI outcomes. BEZ given with SoC significantly reduced rCDI in patients with SRI and could benefit this hard to treat population.</offsets></p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0399"></graphic></fig></sec><sec id="s5"><title><offsets xml_i="7112" xml_f="7123" txt_i="1987" txt_f="1998">Disclosures</offsets></title><p><offsets xml_i="7134" xml_f="7135" txt_i="1999" txt_f="2000">
</offsets><bold><offsets xml_i="7141" xml_f="7149" txt_i="2000" txt_f="2008">Y. Golan</offsets></bold><offsets xml_i="7156" xml_f="7549" txt_i="2008" txt_f="2397">, Merck &amp; Co., Inc.: Grant Investigator, Scientific Advisor and Speaker’s Bureau, Research support and Speaker honorarium; Pfizer: Scientific Advisor, Speaker honorarium; Allergab: Grant Investigator and Scientific Advisor, Research grant and Speaker honorarium; The Medicines Company: Scientific Advisor, Speaker honorarium; Seres Pharmaceuticals: Scientific Advisor, Speaker honorarium; </offsets><bold><offsets xml_i="7555" xml_f="7567" txt_i="2397" txt_f="2409">H. L. DuPont</offsets></bold><offsets xml_i="7574" xml_f="7704" txt_i="2409" txt_f="2539">, BioK International, Salix: Consultant, Consulting fee; University Rebiotix, Seres, Takeda: Grant Investigator, Grant recipient; </offsets><bold><offsets xml_i="7710" xml_f="7721" txt_i="2539" txt_f="2550">F. Aldomiro</offsets></bold><offsets xml_i="7728" xml_f="7867" txt_i="2550" txt_f="2681">, BMS &amp; ViiV: Scientific Advisor, Consulting fee; MSD, Viiv, Astellas &amp; Pfizer: Participated in Clinical Trials, Research support; </offsets><bold><offsets xml_i="7873" xml_f="7885" txt_i="2681" txt_f="2693">E. H. Jensen</offsets></bold><offsets xml_i="7892" xml_f="7972" txt_i="2693" txt_f="2769">, Merck &amp; Co., Inc.: Employee, may own stock/hold stock options in Company; </offsets><bold><offsets xml_i="7978" xml_f="7990" txt_i="2769" txt_f="2781">M. E. Hanson</offsets></bold><offsets xml_i="7997" xml_f="8080" txt_i="2781" txt_f="2860">, Merck &amp; Co. Inc.: Employee, may own stock/hold stock options in the Company; </offsets><bold><offsets xml_i="8086" xml_f="8096" txt_i="2860" txt_f="2870">M. B. Dorr</offsets></bold><offsets xml_i="8103" xml_f="8201" txt_i="2870" txt_f="2964">, Merck &amp; Co., Inc.: Employee and Shareholder, may own stock/hold stock options in the Company</offsets></p></sec></abstract><counts><page-count count="1"></page-count></counts></article-meta></front></article>